Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

BRIM8: Vemurafenib in high risk melanoma patients

Dr Karl Lewis - University of Colorado Denver, Colorado, USA
BRIM8: Vemurafenib in high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017

COMBI-AD: Dabrafenib plus trametinib in advanced melanoma

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017

Expert commentary on melanoma immunotherapy latest

Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017

Vemurafenib for high risk melanoma patients

Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017

Dabrafenib plus trametinib for stage III mutant melanoma

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017

Nivolumab vs ipilimumab for high risk melanoma patients

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017

Checkmate 238: Adjuvant checkpoint therapy after melanoma resection

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017

The METRIC trial of trametinib, five years on

Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
The METRIC trial of trametinib, five years on ( Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany )
10 Sep 2017

New strategies in melanoma care

Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands
New strategies in melanoma care ( Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2017

Reduced work ability in cancer survivors

Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway
Reduced work ability in cancer survivors ( Dr Cecilie Kiserud - Oslo University Hospital, Oslo, Norway )
9 Sep 2017

Problems with survivorship care in Europe

Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy
Problems with survivorship care in Europe ( Prof Francesco De Lorenzo - University of Naples Federico II, Naples, Italy )
9 Sep 2017

Underprovision and inequality of specialised cancer care

Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Greece
Underprovision and inequality of specialised cancer care ( Dr Emmanouil Saloustros - General Hospital of Heraklion 'Venizelio', Crete, Greece )
9 Sep 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation